Barbara Roniker

8.4k total citations · 2 hit papers
20 papers, 6.2k citations indexed

About

Barbara Roniker is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Barbara Roniker has authored 20 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Cardiology and Cardiovascular Medicine, 15 papers in Endocrinology, Diabetes and Metabolism and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Barbara Roniker's work include Hormonal Regulation and Hypertension (15 papers), Blood Pressure and Hypertension Studies (14 papers) and Sodium Intake and Health (4 papers). Barbara Roniker is often cited by papers focused on Hormonal Regulation and Hypertension (15 papers), Blood Pressure and Hypertension Studies (14 papers) and Sodium Intake and Health (4 papers). Barbara Roniker collaborates with scholars based in United States, United Kingdom and Spain. Barbara Roniker's co-authors include Jay H. Kleiman, Richard M. Bittman, James D. Neaton, Faı̈ez Zannad, Marjorie Gatlin, Felipe A. Martínez, Bertram Pitt, Willem J. Remme, Scott Krause and Robert Weiss and has published in prestigious journals such as New England Journal of Medicine, Circulation and SHILAP Revista de lepidopterología.

In The Last Decade

Barbara Roniker

20 papers receiving 5.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction

2003 3.4k citations Bertram Pitt, Willem J. Remme et al. New England Journal of Medicine profile →
EPLERENONE POST-ACUTE MYOCARDIAL INFARCTION HEART FAILURE EFFICACY AND SURVIVAL STUDY INVESTIGATORS. EPLERENONE, A SELECTIVE ALDOSTERONE BLOCKER, IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL INFARCTION

2003 539 citations B. Pitt, F Zannad et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Barbara Roniker United States	16	4.0k	3.9k	1.6k	1.2k	958	20	6.2k
Marjorie Gatlin United States	10	4.0k 1.0×	3.1k 0.8×	1.3k 0.8×	821 0.7×	748 0.8×	16	5.7k
Jay H. Kleiman United States	14	3.8k 0.9×	2.9k 0.7×	1.4k 0.9×	965 0.8×	736 0.8×	20	5.5k
A.J. Pérez Pérez United States	6	7.0k 1.7×	4.1k 1.1×	1.9k 1.2×	2.0k 1.6×	1.2k 1.2×	11	9.6k
Richard M. Bittman United States	10	3.1k 0.8×	2.4k 0.6×	1.5k 0.9×	833 0.7×	622 0.6×	15	4.9k
Felipe A. Martínez United States	29	5.3k 1.3×	4.2k 1.1×	1.8k 1.1×	1.5k 1.2×	1.2k 1.2×	100	7.9k
F. H. M. Derkx Netherlands	44	3.2k 0.8×	2.1k 0.5×	723 0.4×	1.2k 1.0×	1.6k 1.7×	121	5.7k
Harry Shi United States	23	3.1k 0.8×	1.9k 0.5×	905 0.6×	1.1k 0.9×	541 0.6×	56	4.6k
Kohji Shirai Japan	37	3.0k 0.7×	1.4k 0.4×	1.6k 1.0×	613 0.5×	634 0.7×	152	5.0k
Yves Lacourcière Canada	38	3.8k 0.9×	1.5k 0.4×	654 0.4×	916 0.8×	378 0.4×	148	5.2k
Leonardo A. Sechi Italy	36	2.0k 0.5×	2.8k 0.7×	1.7k 1.1×	415 0.4×	876 0.9×	131	4.8k

Countries citing papers authored by Barbara Roniker

Since Specialization

Citations

This map shows the geographic impact of Barbara Roniker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara Roniker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara Roniker more than expected).

Fields of papers citing papers by Barbara Roniker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara Roniker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara Roniker. The network helps show where Barbara Roniker may publish in the future.

Co-authorship network of co-authors of Barbara Roniker

This figure shows the co-authorship network connecting the top 25 collaborators of Barbara Roniker. A scholar is included among the top collaborators of Barbara Roniker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara Roniker. Barbara Roniker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Weinberger, Myron H., William B. White, Luís M. Ruilope, et al.. (2005). Effects of eplerenone versus losartan in patients with low-renin hypertension. American Heart Journal. 150(3). 426–433. 87 indexed citations

Williams, Gordon H., Ellen Burgess, R. Kolloch, et al.. (2004). Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. The American Journal of Cardiology. 93(8). 990–996. 135 indexed citations

White, William B., et al.. (2003). Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. The American Journal of Cardiology. 92(1). 38–42. 87 indexed citations

Burgess, Ellen, Suzanne Oparil, Jay H. Kleiman, et al.. (2003). Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension. Clinical Therapeutics. 25(9). 2388–2404. 57 indexed citations

Flack, John M., Suzanne Oparil, J. Howard Pratt, et al.. (2003). Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. Journal of the American College of Cardiology. 41(7). 1148–1155. 183 indexed citations

Prisant, L. Michael, Henry Krum, Barbara Roniker, et al.. (2003). Can Renin Status Predict the Antihypertensive Efficacy of Eplerenone Add‐On Therapy?. The Journal of Clinical Pharmacology. 43(11). 1203–1210. 23 indexed citations

White, William B., et al.. (2003). Effects of the Selective Aldosterone Blocker Eplerenone Versus the Calcium Antagonist Amlodipine in Systolic Hypertension. Hypertension. 41(5). 1021–1026. 237 indexed citations

Pitt, Bertram, Willem J. Remme, Faı̈ez Zannad, et al.. (2003). Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. New England Journal of Medicine. 348(14). 1309–1321. 3443 indexed citations breakdown →

Pitt, B., F Zannad, James D. Neaton, et al.. (2003). EPLERENONE POST-ACUTE MYOCARDIAL INFARCTION HEART FAILURE EFFICACY AND SURVIVAL STUDY INVESTIGATORS. EPLERENONE, A SELECTIVE ALDOSTERONE BLOCKER, IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL INFARCTION. 348. 1309–1321. 539 indexed citations breakdown →

10.

Pitt, Bertram, Nathaniel Reichek, Roland Willenbrock, et al.. (2003). Effects of Eplerenone, Enalapril, and Eplerenone/Enalapril in Patients With Essential Hypertension and Left Ventricular Hypertrophy. Circulation. 108(15). 1831–1838. 480 indexed citations

11.

Krum, Henry, Richard D. Gordon, H Nolly, et al.. (2002). Co-Administration of Eplerenone with an Angiotensin-Converting Enzyme Inhibitor or an Angiotensin II Antagonist in Patients with Mild to Moderate Hypertension. Japanese Circulation Journal-english Edition. 66. 561. 6 indexed citations

12.

Pitt, Bertram, Vivencio Barrios, Barbara Roniker, et al.. (2002). Efficacy and Safety of Eplerenone Compared to Enalapril in Left Ventricular Hypertrophy. Japanese Circulation Journal-english Edition. 66. 139. 1 indexed citations

13.

Weinberger, M H, Barbara Roniker, Scott Krause, & Robert Weiss. (2002). Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. American Journal of Hypertension. 15(8). 709–716. 307 indexed citations

14.

Epstein, Murray, et al.. (2002). Eplerenone reduces proteinuria in type II diabetes mellitus: implications for aldosterone involvement in the pathogenesis of renal dysfunction. Journal of the American College of Cardiology. 39. 249–249. 32 indexed citations

15.

Krum, Henry, H Nolly, Weizhong He, et al.. (2002). Efficacy of Eplerenone Added to Renin-Angiotensin Blockade in Hypertensive Patients. Hypertension. 40(2). 117–123. 174 indexed citations

16.

Delyani, John A., Ricardo Rocha, Chyung S. Cook, et al.. (2001). Eplerenone: A Selective Aldosterone Receptor Antagonist (SARA). Cardiovascular Drug Reviews. 19(3). 185–200. 93 indexed citations

17.

Wittes, Janet, Desmond G. Julian, Jean‐Pierre Boissel, et al.. (2001). Experience collecting interim data on mortality: an example from the RALES study. SHILAP Revista de lepidopterología. 2(1). 59–62. 7 indexed citations

18.

Pitt, Bertram, Gordon H. Williams, Willem J. Remme, et al.. (2001). The EPHESUS Trial: Eplerenone in Patients with Heart Failure Due to Systolic Dysfunction Complicating Acute Myocardial Infarction. Cardiovascular Drugs and Therapy. 15(1). 79–87. 259 indexed citations

19.

Young, Antony R., T Fakouhi, Graham I. Harrison, et al.. (1996). The UVR wavelength dependence for lomefloxacin photosensitization of human skin. Journal of Photochemistry and Photobiology B Biology. 32(3). 165–170. 10 indexed citations

20.

Lowe, Nicholas J., et al.. (1994). Photoreactions with a fluoroquinolone antimicrobial: Evening versus morning dosing. Clinical Pharmacology & Therapeutics. 56(5). 587–591. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact